(Q45221259)

11 December 2017

title

Cost-effectiveness treatment with Rituximab in patients with rheumatoid arthritis in real life (English)

1 reference

11 December 2017

1 reference

1 reference

Maurizio Benucci

1

1 reference

11 December 2017

Gianantonio Saviola

series ordinal

2

1 reference

11 December 2017

Paola Baiardi

series ordinal

3

1 reference

11 December 2017

Mariangela Manfredi

series ordinal

4

1 reference

11 December 2017

publication date

16 May 2010

1 reference

Rheumatology International

11 December 2017

published in

1 reference

11 December 2017

volume

31

1 reference

11 December 2017

issue

11

1 reference

11 December 2017

page(s)

1465-1469

1 reference

https://scigraph.springernature.com/pub.10.1007/s00296-010-1502-6

11 December 2017

exact match

0 references

cites work

Modeling the progression of rheumatoid arthritis: a two-country model to estimate costs and consequences of rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Measurement of health state utilities for economic appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Rheumatoid arthritis: what does it cost and what factors are driving those costs? Results of a survey in a community-derived population in Malmö, Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00296-010-1502-6

Budget impact model of rituximab after failure of one or more TNFalpha inhibitor therapies in the treatment of rheumatoid arthritis.

21 January 2018

1 reference

12 December 2020

Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register

1 reference

12 December 2020

The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients

1 reference

12 December 2020

Prevalence of musculoskeletal conditions in an Italian population sample: results of a regional community-based study. I. The MAPPING study

1 reference

12 December 2020

Rituximab in the treatment of rheumatoid arthritis patients in Italy: a budget impact analysis

1 reference

12 December 2020

A multicenter cost-of-illness study on rheumatoid arthritis in Italy

1 reference

12 December 2020

UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug

1 reference

12 December 2020

B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents

1 reference

12 December 2020

Clinical protocol for monitoring of targeted therapies in rheumatoid arthritis

1 reference

12 December 2020

10.1007/S00296-010-1502-6

Identifiers

DOI

1 reference

Dimensions Publication ID

11 December 2017

1016182831

0 references

1 reference